340570.KQ
T&L Co., Ltd.
KOE · Healthcare · Medical - Devices · KR
KRW 29,300.00
−2.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 175.2B | 164.2B | 174.9B | 115.5B | 81.6B |
| Cost of Revenue | 91.8B | 91.8B | 99.4B | 70.3B | 47.4B |
| Gross Profit | 83.3B | 72.4B | 75.5B | 45.2B | 34.2B |
| Operating Expenses | |||||
| R&D Expense | 4.7B | 4.6B | 3.2B | 3.4B | 2.5B |
| SG&A Expense | 9.0B | 8.7B | 5.2B | 3.2B | 2.1B |
| General & Admin Expense | 1.4B | 1.9B | 1.6B | 1.3B | 1.0B |
| Selling & Marketing Expense | 3.9B | 6.8B | 3.6B | 1.9B | 1.0B |
| Other Expenses | 10.3B | 12.8B | 10.1B | 7.7B | 5.3B |
| Total Operating Expenses | 24.0B | 26.0B | 18.5B | 14.3B | 9.9B |
| Cost and Expenses | 115.8B | 117.8B | 117.9B | 84.6B | 57.3B |
| Operating Income (EBIT) | 59.4B | 46.4B | 57.0B | 30.8B | 24.3B |
| Non-Operating | |||||
| Interest Income | 2.0B | 1.9B | 1.9B | 1.2B | 677.4M |
| Interest Expense | 9.3M | 13.4M | 19.6M | 8.7M | 33.5M |
| Net Interest Income | 2.0B | 1.9B | 1.9B | 1.2B | 643.9M |
| Other Non-Op Income/Expense | 5.8B | 1.5B | 5.3B | 2.2B | 1.3B |
| Non-Operating Income (excl Interest) | (4.2B) | (1.5B) | (5.3B) | (2.2B) | (1.3B) |
| EBT (Pre-Tax Income) | 65.2B | 47.8B | 62.3B | 33.1B | 25.6B |
| Income Tax Expense | 14.4B | 9.7B | 15.9B | 5.6B | 4.4B |
| Bottom Line | |||||
| Net Income | 50.8B | 38.1B | 46.4B | 27.4B | 21.1B |
| Earnings from Cont. Ops | 50.8B | 38.1B | 46.4B | 27.4B | 21.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 50.8B | 38.1B | 46.4B | 27.4B | 21.1B |
| Per Share | |||||
| Basic EPS | ₩3,162 | ₩2,363 | ₩2,875 | ₩1,700 | ₩1,301 |
| Diluted EPS | ₩3,162 | ₩2,363 | ₩2,875 | ₩1,700 | ₩1,301 |
| Revenue Per Share | ₩10,926 | ₩10,186 | ₩10,833 | ₩7,151 | ₩5,026 |
| Shares | |||||
| Basic Shares Outstanding | 16.0M | 16.1M | 16.1M | 16.1M | 16.2M |
| Diluted Shares Outstanding | 16.0M | 16.1M | 16.1M | 16.1M | 16.2M |
| Profitability Metrics | |||||
| EBITDA | 68.5B | 52.5B | 66.2B | 35.9B | 27.7B |
| D&A | 4.8B | 4.7B | 3.9B | 2.8B | 2.1B |
| EBIT | 63.6B | 47.8B | 62.3B | 33.1B | 25.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026